Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-08-12

Clinical Trial Update: Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab in combination with GM-CSF for chronic lymphocytic leukemia; the study is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Leukine (sargramostim)
  • Rituxan (rituximab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Leukemia | Phase 2 | Status: TERMINATED